Loading clinical trials...
Loading clinical trials...
A Phase II Randomized Window of Opportunity Trial Evaluating Clinical and Biological Effects of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer
Conditions
Interventions
GSK3326595
Locations
1
Canada
St. Joseph's Health Care London
London, Ontario, Canada
Start Date
June 8, 2021
Primary Completion Date
August 15, 2022
Completion Date
August 15, 2022
Last Updated
October 25, 2022
NCT05372640
NCT04704661
NCT05673200
NCT04550494
NCT05245812
NCT07483307
Lead Sponsor
Ottawa Hospital Research Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions